Louis Lacombe
Chercheur universitaire clinicien
Axe Oncologie
Publications
View all-
article Feng T, Xie N, Gao L, Jia Q, Kung S, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression
J Clin Invest 2025.
-
article Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É and Guillemette C
Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer
BMC Cancer 25 (1), 2025.
-
article Uchil A, Lacombe L, Hovington H, Brisson H, Simonyan D, Caron P, Ouellet V, Latour M, Aprikian A, Bergeron A, Chevalier S, McKercher G, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Carmel M, Hamilou Z, Trudel D, van der Kwast T, Mes-Masson AM, Dong X, Saad F, Guillemette C, Lévesque E
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Netwo…
Eur Urol Oncol 2025.
Projects
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
- Biobangue Procure, from 2025-03-01 to 2029-03-30
- Aberrant UGT2B28 androgen inactivation pathway predict prostate cancer progression., from 2022-02-05 to 2027-03-31
- Biobangue UR0-1, from 2025-03-01 to 2029-03-30
- Metabolomics and lipidomics of prostate cancer progression: Leveraging the PROCURE, from 2025-03-01 to 2027-03-30
- Étude sur le role de la voie des glycosyltransferase CUGT) en cancer de la vessie, from 2025-03-01 to 2030-03-30
- Soutien à la recherche, from 2017-07-01 to 2024-06-30
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , from 2024-06-17 to 2025-06-16
- Metabolomics and lipidomics of prostate cancer progression: Leveraging the PROCURE Biobank, from 2024-07-10 to 2025-03-31